The Quality Lowdown: US FDA Renews Attention To Contamination Challenges
Executive Summary
All-out efforts by agency staff to help industry supply COVID-19 treatments last year were applauded but now its attention returns to the top pre-pandemic priority, contamination risks. Edge Pharma consents to attack mold, Glicerinas blocked over inspection refusal, Bioiberica hit for ‘reprocessing’ contaminated drug substance, Rentschler bashed for inadequate monitoring.
You may also be interested in...
US FDA Would Allow Separation Alternatives In Manufacture Of Low-Risk Beta-Lactams
Proposed guidance revision adds nuance to manufacturing facility separation expectations for beta-lactam compounds that pose less risk of anaphylaxis than penicillin and related antibiotics.
Continuous Pharmaceutical Manufacturing Bill Hitches A Ride With US FDA User Fee Legislation
US legislation could advance new manufacturing platforms for drugs and biologics with academic R&D and workforce development and in turn spur domestic growth.
US FDA Poses Next-Level GMP Challenges For Aurobindo's Polepally Site
Agency conducts follow-up inspection as Aurobindo's Polepally, India, manufacturing facility looks to move on from crippling OAI designation.